Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells.

Circulating tumor cells (CTCs), which are captured from blood with anti-epithelial cell adhesion molecule (EpCAM) antibodies, have established prognostic value in specific epithelial cancers, but less is known about their utility for assessing patient response to molecularly targeted agents via measurement of pharmacodynamic (PD) endpoints. We discuss the use of CellSearch (Janssen Diagnostics, LLC, Raritan, NJ) CTC isolation technology for monitoring PD response in early phase trials. We present representative data from three clinical trials with the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) suggesting that CTCs can be used to measure PD effects. However, while often leading to hypothesis-generating information, our experience points to the difficulty in obtaining sufficient EpCAM-expressing CTCs from patients with advanced disease to reach statistically significant conclusions about PD effects from each trial. Overall, the level of phenotypic heterogeneity observed in specimens from patients with advanced carcinomas suggests caution in the use of cell-surface differentiation marker-based methods for isolating CTCs.

[1]  E. Rogakou,et al.  DNA Double-stranded Breaks Induce Histone H2AX Phosphorylation on Serine 139* , 1998, The Journal of Biological Chemistry.

[2]  Jonathan W. Uhr,et al.  Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.

[3]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[4]  Tanja Fehm,et al.  Circulating Tumor Cells in Patients with Breast Cancer Dormancy , 2004, Clinical Cancer Research.

[5]  G. T. Budd,et al.  Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival , 2006, Clinical Cancer Research.

[6]  A. Adjei,et al.  Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor , 2007, Clinical Cancer Research.

[7]  K. Pienta,et al.  Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.

[8]  Michael Morse,et al.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Shoemaker,et al.  Immunohistochemical Discrimination Between the ASPL-TFE3 Fusion Proteins of Alveolar Soft Part Sarcoma , 2008, Journal of pediatric hematology/oncology.

[10]  D. Dearnaley,et al.  Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. , 2009, Cancer research.

[11]  Hartwig Huland,et al.  Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival. , 2009, Clinical chemistry.

[12]  J. Chalmers,et al.  Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells , 2009, Biotechnology and bioengineering.

[13]  Yvonne A. Evrard,et al.  Development of a Validated Immunofluorescence Assay for γH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity , 2010, Clinical Cancer Research.

[14]  Bo Lu,et al.  A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on a microfilter. , 2010, Cancer research.

[15]  D. Dearnaley,et al.  Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Teknos,et al.  Significance of circulating tumor cells in patients with squamous cell carcinoma of the head and neck: initial results. , 2010, Archives of otolaryngology--head & neck surgery.

[17]  Yvonne A. Evrard,et al.  Monitoring Drug-Induced γH2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells , 2010, Clinical Cancer Research.

[18]  K. Isselbacher,et al.  Isolation of circulating tumor cells using a microvortex-generating herringbone-chip , 2010, Proceedings of the National Academy of Sciences.

[19]  S. Groshen,et al.  Portable Filter-Based Microdevice for Detection and Characterization of Circulating Tumor Cells , 2010, Clinical Cancer Research.

[20]  J. Dempsey,et al.  Abstract A49: Circulating tumor cell (CTC) assay development for detection of H2AX as a clinical pharmacodynamic (PD) marker for Chk1 kinase inhibitors. , 2011 .

[21]  E. Sausville,et al.  Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in combination with irinotecan (CPT-11; Ir) in patients (pts) with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  H. Scher,et al.  TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. , 2011, European urology.

[23]  L. Frati,et al.  Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  R. Pethig,et al.  ApoStream(™), a new dielectrophoretic device for antibody independent isolation and recovery of viable cancer cells from blood. , 2012, Biomicrofluidics.

[25]  F. Heitz,et al.  Requirements to Assess Feasibility of Phase 0 Trials during Major Abdominal Surgery: Variability of PARP Activity , 2012, Clinical Cancer Research.

[26]  Caroline Dive,et al.  Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Larry Rubinstein,et al.  A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas , 2012, Clinical Cancer Research.

[28]  H. Wakelee,et al.  ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. , 2012, Lung cancer.

[29]  Harris Markomanolaki,et al.  Apoptotic Circulating Tumor Cells in Early and Metastatic Breast Cancer Patients , 2013, Molecular Cancer Therapeutics.

[30]  L. Dawson,et al.  A phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis. , 2014 .

[31]  R. Kimmig,et al.  ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance. , 2014, Clinical chemistry.

[32]  Peter R. C. Gascoyne,et al.  Isolation of Circulating Tumor Cells by Dielectrophoresis , 2014, Cancers.

[33]  M. Baker.  Reproducibility crisis: Blame it on the antibodies , 2015, Nature.

[34]  S. Steinberg,et al.  Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer , 2015, Clinical Cancer Research.

[35]  E. Sausville,et al.  Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors , 2016, Clinical Cancer Research.

[36]  L. Dawson,et al.  A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. , 2016, Gynecologic oncology.